Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data

Published:2019-07-06 Issue:1 Volume:4 Page:133-142
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Bullement Ash^ORCID,McMordie Samuel Thomas^ORCID,Hatswell Anthony James^ORCID,Li Nanxin,Wilson Koo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s41669-019-0158-8.pdf

Reference52 articles.

1. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet Lond Engl. 2012;379:1447–56.

2. Lorenzoni V, Triulzi I, Turchetti G. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective. BMC Health Serv Res. 2018;18:596.

3. Kuijlaars IA, Timmer MA, de Kleijn P, Pisters MF, Fischer K. Monitoring joint health in haemophilia: factors associated with deterioration. Haemophilia. 2017;23:934–40.

4. Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorbidity. 2011;1:51–9.

5. O’Hara J, Walsh S, Camp C, Mazza G, Carroll L, Hoxer C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16:84.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A;Drugs - Real World Outcomes;2024-08-10

2. Proof-of-Concept Study of a 3-D Ultrasound Scanner Used for Ankle Joint Assessment;Ultrasound in Medicine & Biology;2023-01

3. Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada;Haemophilia;2022-12-18

4. Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe;Journal of Medical Economics;2022-09-06

5. Efmoroctocog Alfa: A Review in Haemophilia A;Drugs;2021-11